logo
What is chronic venous insufficiency?

What is chronic venous insufficiency?

The Hill17-07-2025
(NEXSTAR) — The White House on Thursday said President Donald Trump was found to have chronic venous insufficiency after undergoing medical testing for 'mild swelling' in his legs and bruising on one of his hands.
A note from Trump's physician shared by press secretary Karoline Leavitt said the 79-year-old president underwent ultrasounds and a 'comprehensive exam' that included a diagnostic vascular study, The Hill previously reported.
Chronic venous insufficiency, or CVI, typically affects people over the age of 50, according to the Cleveland Clinic. The older a person gets, the higher the risk of CVI becomes. It affects roughly 1 in 20 people, the health system says.
Trump undergoes medical exam for swelling in legs, hand bruising
Generally speaking, CVI is when the veins in your legs do not allow blood to flow back up to your heart, Johns Hopkins Medicine explains. Blood can flow backward, leading it to pool in your legs.
Untreated, a person with CVI may experience pain, swelling, cramps, changes to their skin, leg ulcers, and varicose veins. While not a serious health threat, according to Johns Hopkins, 'it can be painful and disabling.'
In addition to age, your weight, family history, and any damage to your leg can cause CVI. People who are pregnant have also been known to develop the condition, per Johns Hopkins. Smoking, a lack of exercise, high blood pressure in the leg veins, deep vein thrombosis, and swelling may also cause CVI.
Despite Trump's diagnosis, the exam did not show any evidence of deep vein thrombosis, his physician said.
Deep vein thrombosis, or DVT, is when one or more blood clots form within the deep veins of your body. Often, those veins are in your legs, according to the Mayo Clinic. Swelling or pain in the legs are common symptoms.
The Cleveland Clinic explains that treatment for CVI can include compression therapy and lifestyle changes, like exercising, elevating the legs, and managing weight.
As for the bruising on his hands, Trump's physician said it was 'consistent with minor soft tissue damage from frequent handshaking.'
in 'excellent health.'
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Kyverna Appoints New CFO to Guide Next Growth Phase
Kyverna Appoints New CFO to Guide Next Growth Phase

Yahoo

time2 minutes ago

  • Yahoo

Kyverna Appoints New CFO to Guide Next Growth Phase

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) is one of the 11 Best New Penny Stocks to Buy Right Now. On June 30, Kyverna Therapeutics, Inc. (NASDAQ:KYTX) announced that Marc Grasso, M.D. has been appointed as the company's new Chief Financial Officer (CFO). Before joining Kyverna Therapeutics, Inc. (NASDAQ:KYTX), Dr. Grasso was serving as CFO at Alector, Inc., a biotechnology company focused on neurodegenerative diseases. There, he oversaw financial planning, investor relations, accounting, IT, and facilities. Dr. Grasso earned his medical degree from Johns Hopkins University School of Medicine, where he also performed research in molecular oncology. He holds a Bachelor of Arts degree in molecular biology with honors from Princeton University. A lab setting filled with scientific equipment and researchers in lab coats working together to develop new therapies for autoimmune diseases. Dr. Grasso has over 25 years of experience working with public companies, capital markets, and investment banking. He is taking over from Ryan Jones, MBA, who is moving to a strategic advisor role to help with a smooth transition. The new CFO is expected to use his experience to help Kyverna Therapeutics, Inc. (NASDAQ:KYTX) bring the first CAR T-cell therapy for autoimmune diseases to the market while also guiding the company's business and financial plans. As Kyverna Therapeutics, Inc. (NASDAQ:KYTX) works to speed up its clinical development and commercialization efforts, Dr. Grasso's leadership will play a crucial role in supporting the company's next phase of growth. Kyverna Therapeutics, Inc. (NASDAQ:KYTX) is a clinical-stage biopharmaceutical company committed to developing cell therapies for patients suffering from autoimmune diseases. While we acknowledge the potential of KYTX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Best American Semiconductor Stocks to Buy Now and 11 Best Fintech Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.

Stifel Keeps Buy Rating on Alto Neuroscience (ANRO)
Stifel Keeps Buy Rating on Alto Neuroscience (ANRO)

Yahoo

time2 minutes ago

  • Yahoo

Stifel Keeps Buy Rating on Alto Neuroscience (ANRO)

Alto Neuroscience, Inc. (NYSE:ANRO) is one of the 11 Best New Penny Stocks to Buy Right Now. On June 26, Stifel reiterated its 'Buy' rating on Alto Neuroscience, Inc. (NYSE:ANRO) with a price target of $10. This decision came after the company announced Phase 2 proof-of-concept results for its drug ALTO-203 in major depressive disorder (MDD) patients with elevated levels of anhedonia. A close-up of a healthcare professional in a lab coat, handling a pipette with medications for neuroscience diseases. The trial showed mixed results. However, Stifel analysts noted that ALTO-203 showed significant positive effects in improving sustained attention and increased wakefulness. The strongest results were seen in patients with more abnormal theta/beta EEG ratios at baseline, which is a biomarker that can be used to help diagnose ADHD. Stifel described the trial as exploratory with low expectations, noting that although this program keeps some options open for Alto Neuroscience, Inc. (NYSE:ANRO), it does not change the core investment view as the company prioritizes its late-stage pipeline. The next steps for ALTO-203 are yet to be determined. Alto Neuroscience, Inc. (NYSE:ANRO) is a clinical-stage biopharmaceutical company focused on the development of treatment options for neuropsychiatric disorders. While we acknowledge the potential of ANRO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Best American Semiconductor Stocks to Buy Now and 11 Best Fintech Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Fehler beim Abrufen der Daten Melden Sie sich an, um Ihr Portfolio aufzurufen. Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten

Canaccord Genuity Reiterates Buy Rating on Fractyl Health (GUTS)
Canaccord Genuity Reiterates Buy Rating on Fractyl Health (GUTS)

Yahoo

time2 minutes ago

  • Yahoo

Canaccord Genuity Reiterates Buy Rating on Fractyl Health (GUTS)

Fractyl Health, Inc. (NASDAQ:GUTS) is one of the 11 Best New Penny Stocks to Buy Right Now. On July 18, Canaccord Genuity reiterated its 'Buy' rating on Fractyl Health, Inc. (NASDAQ:GUTS) with a price target of $12. This decision came after the company had shared new data from its Phase 3 trial of its lead product candidate, Revita. A medical laboratory surrounded by advanced equipment, symbolizing the company's cutting-edge innovation in healthcare. Canaccord Genuity had follow-up discussions with several physicians following the data presented by Fractyl Health, Inc. (NASDAQ:GUTS) from the open-label group of its ongoing Phase 3 trial for Revita in weight maintenance at the American Diabetes Association meeting. These physicians who were consulted by the investment firm were all from large academic hospitals in the US. The physicians had different opinions on the mechanism behind the Revita procedure and the potential market size. However, they all agreed that controlled data is needed to fully assess the clinical profile. The physicians said the main concern is the durability of the effect. Canaccord pointed out that even conservative market share estimates from the physicians surpassed the firm's current modeling expectations. Canaccord Genuity expects Revita to reach 1% peak penetration in the weight maintenance population with a 60% probability of success. The investment firm projects that peak sales could reach $400 million in 2031. Fractyl Health, Inc. (NASDAQ:GUTS) is a metabolic therapeutics company focused on pursuing therapies that target root causes of obesity and type 2 diabetes. While we acknowledge the potential of GUTS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Best American Semiconductor Stocks to Buy Now and 11 Best Fintech Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store